Clinical Trials Logo

Bladder Urothelial Carcinoma clinical trials

View clinical trials related to Bladder Urothelial Carcinoma.

Filter by:

NCT ID: NCT06416319 Recruiting - Bladder Cancer Clinical Trials

Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)

PreAct
Start date: March 14, 2023
Phase: N/A
Study type: Interventional

A bicentric, open-label randomised controlled trial (RCT) is planned to investigate whether the use of fitness wristbands in a defined preoperative period prior to radical cystectomy leads to a preoperative increase in participants' physical activity (number of steps per day) up to the day of radical cystectomy.

NCT ID: NCT06263153 Not yet recruiting - Clinical trials for Bladder Urothelial Carcinoma

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based therapy. Cisplatin-based therapy is the standard of care for patients with MIBC. However, many patients cannot receive standard therapy due to poor renal function, peripheral neuropathy, poor functional status, or clinically significant heart failure. Futibatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Radical cystectomy is a surgery to remove all of the bladder as well as nearby tissues and organs. Giving futibatinib in combination with durvalumab before surgery may be an effective treatment option for patients with MIBC who are ineligible for cisplatin-based therapy.

NCT ID: NCT06170177 Recruiting - Bladder Cancer Clinical Trials

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy

Start date: February 4, 2013
Phase:
Study type: Observational

Observational study on the quality of life and pathological state of patients underwent radical cystectomy.

NCT ID: NCT06167356 Recruiting - Bladder Cancer Clinical Trials

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Start date: November 27, 2013
Phase:
Study type: Observational

A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES.

NCT ID: NCT05833997 Recruiting - Bladder Cancer Clinical Trials

Safety Analysis and Oncological Outcomes in HoLERT vs TURBT

Start date: December 10, 2020
Phase: N/A
Study type: Interventional

Bladder urothelial cancer is the second most common urologic tumor and represents a worldwide public health problem. Most cases are diagnosed as non-muscle invasive tumors, and can be treated with transurethral resection of bladder tumor (TURBT). However, the electrical energy-based TURBT fragments the tumor, burning it to its own muscular layer leading to artifacts that may spoil the histopathological analysis, resulting in understaging after the first TURBT ranging from 30-64%, depending on the presence of detrusor muscle. Modern laser technologies have been emerging as an alternative to classical TURB using en bloc tumor resection technique (ERBT). Therefore, the laser is applied on tumor's pedicle to resect the whole and intact tumor without fragmentation or fulguration as occurs in TURBT. The purpose of using laser if to improve the resection quality, decrease intra and perioperative complications, avoid re-TURBT and reduce recurrence rates at the resection site and in distant sites. Thus, the purpose of this study is to evaluate Laser Holmium use for large tumors resection (>3cm), reducing complications, costs, and the need for new approaches, and improving the muscle layers samples.

NCT ID: NCT05788484 Recruiting - Colorectal Cancer Clinical Trials

A Study of CDX-585 in Patients With Advanced Malignancies

Start date: May 11, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

NCT ID: NCT05669430 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Start date: March 23, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

NCT ID: NCT05564416 Withdrawn - Clinical trials for Urothelial Carcinoma

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Start date: October 12, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial compares the effect of erdafitinib alone to using the combination of erdafitinib and atezolizumab in treating patients with bladder cancer whose tumor invades the muscular bladder wall (muscle invasive)and who are ineligible for treatment with a chemotherapy drug called cisplatin. This trial also determines whether these treatment approaches are better than the usual approach for treating this type of cancer. The usual approach for treatment of someone with muscle invasive bladder cancer is chemotherapy with a drug called cisplatin followed by surgery (most common), or chemoradiation (radiation combined with chemotherapy) to the bladder (in some patients). However, half of the patients cannot get cisplatin due to safety concerns. This study has a screening step. The purpose of this step is to test patient's tumor to find out if it has a specific change (alteration) in the fibroblast growth factor receptor (FGFR) gene to determine patient's eligibility for this trial. Alteration of the FGFR gene causes bladder cancer cells to grow and divide abnormally. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein. This may help keep cancer cells from growing and may kill them. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving erdafitinib alone or in combination with atezolizumab may help to shrink tumor cells at the time of surgery better than the usual treatment in muscle invasive bladder cancer.

NCT ID: NCT05296564 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Start date: April 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers

NCT ID: NCT05220124 Recruiting - Clinical trials for Bladder Urothelial Carcinoma

A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma

Start date: January 5, 2022
Phase: Phase 4
Study type: Interventional

A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.